Last updated on February 2018

Study to Evaluate the Safety Tolerability Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme


Brief description of study

This study evaluates the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNasein Patients with Cystic Fibrosis previously treated with Pulmozyme.

Detailed Study Description

This is a proof-of-concept, open label study, to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of 2.5 mg AIR DNase TM administered once daily for 28 days via inhalation to Cystic Fibrosis subjects who have previously been treated with Pulmozyme.

This multicenter study will be conducted in approximately 10 sites and will enroll up to 15 subjects.

Clinical Study Identifier: NCT02722122

Find a site near you

Start Over

Hadassah MC

Jerusalem, Israel
  Connect »